Mark W. Frohlich's most recent trade in Rigel Pharmaceuticals was a trade of 12,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 6, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Rigel Pharmaceuticals | Mark W. Frohlich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 12,000 | 12,000 | - | - | Stock Option (right to buy) |